* Cardiff Oncology Inc is expected to show a fall in quarterly revenue when it reports results on May 2 for the period ending March 31 2024
* The San Diego California-based company is expected to report a 33.7% decrease in revenue to $55 thousand from $83 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Cardiff Oncology Inc is for a loss of 25 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Cardiff Oncology Inc is $10.50, above its last closing price of $4.36.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jan. 1 0001 -0.27 -0.28 -0.21 Beat 24.3
Sep. 30 0001 -0.28 -0.28 -0.22 Beat 22.8
Jun. 30 2023 -0.28 -0.26 -0.25 Beat 3.5
Mar. 31 2023 -0.22 -0.23 -0.25 Missed -10.6
Dec. -0.22 -0.23 -0.20 Beat 14.9
31 2022
Sep. 30 2022 -0.27 -0.26 -0.20 Beat 24.2
Jun. 30 2022 -0.26 -0.25 -0.24 Beat 4.8
Mar. 31 2022 -0.25 -0.23 -0.25 Missed -8.2
This summary was machine generated April 30 at 22:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments